BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IFN-alpha kinoid: Preliminary Phase I/II data

Preliminary data from the double-blind, placebo-controlled, dose-escalation, European Phase I/II IFN-K-001 trial in 20 patients with mild to moderate lupus showed that 30, 60 and 120 µg doses of intramuscular IFN-K were safe and led...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >